LEXARIA BIOSCIENCE CORP. Long-term Investments and Receivables, Net
LEXARIA BIOSCIENCE CORP. (LEXX) had Long-term Investments and Receivables, Net of $64.01 thousand as of 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:LongTermInvestmentsAndReceivablesNet · last filed 2026-07-13
- 2026-05-31: Long-term Investments and Receivables, Net $64.01K.
- 2026-02-28: Long-term Investments and Receivables, Net $64.01K.
- 2025-11-30: Long-term Investments and Receivables, Net $64.01K.
- 2025-08-31: Long-term Investments and Receivables, Net $64.01K.
| Period end | Long-term Investments and Receivables, Net |
|---|---|
| 2026-05-31 | $64.01K 10-Q · filed 2026-07-13 |
| 2026-02-28 | $64.01K 10-Q · filed 2026-04-13 |
| 2025-11-30 | $64.01K 10-Q · filed 2026-01-13 |
| 2025-08-31 | $64.01K 10-Q · filed 2026-07-13 |
| 2025-05-31 | $64.01K 10-Q · filed 2025-07-14 |
| 2025-02-28 | $64.01K 10-Q · filed 2025-04-14 |
| 2024-11-30 | $64.01K 10-Q · filed 2025-01-10 |
| 2024-08-31 | $63.58K 10-K · filed 2025-11-28 |
| 2023-08-31 | $48.56K 10-K · filed 2024-11-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |